Other Events

Filter by content:

Types

  • MGUS
  • Newly diagnosed multiple myeloma
  • Relapsed/refractory multiple myeloma
  • Smoldering multiple myeloma

Therapeutics

  • Auto-HSCT
  • Bortezomib
  • CAR therapy
  • Carfilzomib
  • CC-93269
  • Cevostamab
  • Ciltacabtagene autoleucel
  • Cyclophosphamide
  • Daratumumab
  • Dexamethasone
  • Elranatamab
  • Etentamig
  • Forimtamig
  • Iberdomide
  • Idecabtagene vicleucel
  • Lenalidomide
  • Linvoseltamab
  • Mezigdomide
  • OriCAR-017
  • Pavurutamab
  • T-cell engagers
  • Talquetamab
  • Teclistamab

Congresses

  • 2021 Symposium
  • 2022 Symposium
  • 2023 Hub event
  • 2024 Symposium
  • ASH 2020
  • COMy 2020
  • COMy 2021
  • EBMT 2020
  • EBMT 2021
  • EHA 2023
  • EHA 2024
  • ESH 2020
  • SOHO 2020

Trials

  • ALCYONE
  • APOLLO
  • ASCENT
  • CANDOR
  • CARTITUDE-1
  • CARTITUDE-5
  • CARTITUDE-6
  • CASTORE
  • 3A06
  • FORTE
  • GEM-CESAR
  • GRIFFIN
  • ICARIA-MM
  • IFM2009
  • IKEMA
  • KarMMa
  • KarMMa-9
  • LINKER-MM1
  • MagnetisMM-3
  • MAIA
  • MajesTEC-1
  • MM-014
  • MonumenTAL-1
  • POLLUX
  • PROMISE
  • QUINTESSENTIAL
  • QUREDEX
  • RedirecTT-1

Expert Opinions

  • Amrita Krishnan
  • Barry Quinn
  • Bruno Paiva
  • Doris Hansen
  • Flaminia Coluzzi
  • Heinz Ludwig
  • Irene Ghobrial
  • Krina Patel
  • María-Victoria Mateos
  • Michael Hudecek
  • Mohamad Mohty
  • Naresh Bumma
  • Noopur Raje
  • Sagar Lonial
  • Sergio Giralt
  • Shaji Kumar
  • Vincent Rajkumar

Educational Resources

  • Multiple Myeloma Hub symposiums
  • Risk scores and prognostic tools
  • Special populations

Key Events

  1. The next wave of immune-based therapies: What you need to know in relapsed/refractory multiple myeloma

    Date: Aug 14, 2024

  2. How to sequence CAR T-cell therapy and bispecific antibodies in relapsed/refractory multiple myeloma

    Date: Aug 12, 2024

  3. Looking to the future of bispecific antibodies in MM, and panelist Q&A

    Date: Apr 9, 2024

  4. Practical management of adverse events with immunotherapies

    Date: Apr 9, 2024

  5. Beyond BCMA: Novel strategies using bispecific antibodies

    Date: Apr 9, 2024

  6. Answering the common challenges facing real-world CAR T-cell therapies

    Date: Jul 26, 2023

  7. Real-world patient cases: CAR T-cell therapy

    Date: Jul 24, 2023

  8. Implementing a holistic pain treatment plan in advanced multiple myeloma

    Date: Dec 8, 2022

  9. Biomarkers and patient eligibility for CAR T-cell therapies in MM

    Date: Jul 21, 2023

  10. Management of pain: Understanding the current needs of patients with multiple myeloma

    Date: Mar 31, 2022